NorthStrive Urges enVVeno to Halt Clinical Spending
NEWPORT BEACH, Calif., March 3, 2026 Investment firm NorthStrive Fund II LP has called on enVVeno Medical Corporation to...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
NEWPORT BEACH, Calif., March 3, 2026 Investment firm NorthStrive Fund II LP has called on enVVeno Medical Corporation to...
NEW YORK, Feb. 24, 2026 — Bristol Myers Squibb announced its participation in the upcoming TD Cowen 46th Annual...
HOUSTON | January 6, 2026 — FibroBiologics, Inc. announced that its Founder and Chief Executive Officer will present at...
Prague, Czech Republic; London, UK; Chicago, US – September 11, 2025 – Zentiva, a leading European generics pharmaceutical company,...
